Abstract
Guidelines can be developed on a national or multinational level. There are discussions concerning the relevance of different guidelines at different regional levels. Guidelines’ evaluation can be approached by looking at the items “awareness”, “agreement”, “adoption” and “adherence”. To assess the awareness of national and European (EDF/EADV) guidelines as a means of guidelines’ evaluation. Online survey in five selected European countries (Germany [D], Spain [E], France [F], Italy [I], and the United Kingdom [UK]) among 257 dermatologists assessing awareness of different guidelines (European [EDF/EADV], German, Spanish, French, British). Participants were volunteers registered with a field market research company database. Mean awareness of EDF/EADV guidelines in all countries was 54 %, with lower results in the UK (33 %) and Germany (37 %) and higher awareness in Spain (63 %) and Italy (79 %). Awareness of the national guidelines was very high within the respective countries (mean 92 %). The European guidelines where always the best known guidelines after the respective national guidelines. The most important tools for dissemination of all guidelines were the original publication (63 %) and scientific presentations (46 %).This study identified widespread interest in guidelines as assessed by the grade of awareness. Awareness of European guidelines was higher in countries with late development of national guidelines (i.e. Spain and Italy) compared to countries with early development of own national guidelines such as Germany and the UK. National guidelines can reach almost complete awareness within their respective countries. The original publication is still the most important dissemination tool for guidelines.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ebben RH, Vloet LC, Verhofstad MH, Meijer S, Groot JA, van Achterberg T (2013) Adherence to guidelines and protocols in the prehospital and emergency care setting: a systematic review. Scand J Trauma Resusc Emerg Med 21:9
Lloyd JS, Abrahamson S (1979) Effectiveness of continuing medical education: a review of the evidence. Eval Health Prof 2:251–280
Mrowietz U, Kragballe K, Nast A, Reich K (2011) Strategies for improving the quality of care in psoriasis with the use of treatment goals—a report on an implementation meeting. J Eur Acad Dermatol Venereol 25(Suppl 3):1–13
Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B (2006) S3-Guidelines for the therapy of psoriasis vulgaris. J Dtsch Dermatol Ges 4(Suppl 2):S1–S126
Nast A, Erdmann R, Pathirana D, Rzany B (2008) Translating psoriasis treatment guidelines into clinical practice—the need for educational interventions and strategies for broad dissemination. J Eval Clin Pract 14:803–806
Nast A, Erdmann R, Hofelich V, Reytan N, Orawa H, Sterry W, Rzany B (2009) Do guidelines change the way we treat? Studying prescription behaviour among private practitioners before and after the publication of the German Psoriasis Guidelines. Arch Dermatol Res 301:553–559
Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Muller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B (2011) S3-guidelines for the treatment of psoriasis vulgaris update 2011. J Dtsch Dermatol Ges 9(Suppl 2):S1–S104
Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Muller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B (2012) German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 304:87–113
Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Muller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B (2012) S3-Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 10(Suppl 2):S1–S95
Nederlandse Vereniging voor Dermatologie en Venerologie (NVDV) and the Institute for Healthcare Improvement (CBO) (2003) Dutch Guideline for the treatment of severe psoriasis (ultraviolet B, ultraviolet A in combination with oral psoralen, cyclosporin A, methotrexate and acitretine). Van Zuiden Communications, Netherlands
Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Honigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B (2009) European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 23(Suppl 2):1–70
Pathman DE, Konrad TR, Freed GL, Freeman VA, Koch GG (1996) The awareness-to-adherence model of the steps to clinical guideline compliance. The case of pediatric vaccine recommendations. Med Care 34:873–889
Paul C, Gallini A, Maza A, Montaudie H, Sbidian E, Aractingi S, Aubin F, Bachelez H, Cribier B, Joly P, Jullien D, le Maitre M, Misery L, Richard MA, Ortonne JP (2011) Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 25(Suppl 2):2–11
Puig L, Carrascosa JM, Dauden E, Sanchez-Carazo JL, Ferrandiz C, Sanchez-Regana M, Garcia-Bustinduy M, Bordas X, Moreno JC, Hernanz JM, Laguarda S, Garcia-Patos V (2009) Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents. Actas Dermosifiliogr 100:386–413
Radtke MA, Reich K, Blome C, Kopp I, Rustenbach SJ, Schafer I, Augustin M (2009) Evaluation of quality of care and guideline-compliant treatment in psoriasis. Development of a new system of quality indicators. Dermatology 219:54–58
Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD (2005) British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 153:486–497
Spuls PI, Tuut MK, van Everdingen JJ, de Rie MA (2004) The practice guideline ‘Photo(chemo)therapy and systemic therapy in severe chronic plaque-psoriasis’. Ned Tijdschr Geneeskd 148:2121–2125
Wakkee M, Lugtenberg M, Spuls PI, de Jong EM, Thio HB, Westert GP, Nijsten T (2008) Knowledge, attitudes and use of the guidelines for the treatment of moderate to severe plaque psoriasis among Dutch dermatologists. Br J Dermatol 159:426–432
World Health Organization. Global Programme on Evidence for Health Policy EIP/GPE/EQC/2003.1. Guidelines for WHO guidelines. http://whqlibdoc.who.int/hq/2003/EIP_GPE_EQC_2003_1.pdf. Accessed on 10th May 2012
Acknowledgments
This paper summarises the barrier results from the Progressive Psoriasis Initiative (PPI) Treatment Barriers survey, which was conducted in September/October 2011. The medical research company MEDEFIELD performed the survey. Abbott solely funded the Progressive Psoriasis Initiative programme. The PPI programme and all content was funded through an educational grant to the Medical Center Schleswig-Holstein, Kiel, Germany from Abbott. The PPI programme was led by a Steering Committee whose goal was to (1) define and gain European consensus on treatment goals and (2) to gain international consensus on how to optimize treatment transition for patients with moderate-to-severe plaque-psoriasis. Abbott provided funding to the medical communications agency Lucid, Burleighfield House, Loudwater, UK, to manage the PPI programme that led to the development of this manuscript. Elaine Bell (Lucid) provided editorial support for the authors in the development of this manuscript. Abbott paid consultancy fees to members of the Steering Committee for their participation at Steering Committee meetings and reimbursed travel costs. No payments were made to the authors for the writing of this manuscript. Abbott had no influence on the development of the manuscript nor did it review the content of the manuscript. The authors (all of whom are members of the PPI Steering Committee) determined and approved the final content of the manuscript. This work was funded through an educational grant to the Medical Center Schleswig-Holstein, Kiel, Germany from Abbott.
Conflict of interest
No product was being studied; financial support for an unrestricted educational grant for the “progressive psoriasis initiative” was given by Abbott. AN has received honoraria for CME certified educational talks that received indirect sponsorship from Abbott and Janssen-Cilag; the dEBM (his employer) has received research grants from Wyeth (now Pfizer). UM has been a consultant and/or speaker and/or participant in clinical trials and/or received grants from the following companies that manufacture drugs for the treatment of psoriasis including Abbott, Almirall-Hermal, BiogenIdec, Celgene, Centocor, Forward Pharma, Janssen, Leo Pharma, Medac, MSD Sharp & Dohme, Novartis, Pfizer. KK declares that he has served as advisor, speaker and/or investigator for Abbott, Janssen, Leo Pharma, MSD and Pfizer. LP has served as consultant and/or paid speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis including Abbott, Celgene, Centocor, Janssen-Cilag, Leo, Merck, MSD (formerly Schering-Plough), Novartis, Pfizer (formerly Wyeth). KR has received honoraria as a consultant and/or advisory board member and/or acted as a paid speaker and/or participated in clinical trials sponsored by Abbott, Amgen, Biogen-Idec, Centocor, MSD (formerly Essex Pharma, Schering Plough), UCB, Janseen-Cilag, Celgene, Pfizer (formerly Wyeth), Novartis, LEO Pharma, Basilea, Forward Pharma, Medac and Ocean Pharma.RBW has acted a consultant and/or speaker for Abbott, Pfizer, Janssen, Leo and Schering Plough (now MSD). JS has acted as a paid speaker for Novartis and Abbott, and received research grants from Pfizer (formerly Wyeth) and from Novartis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nast, A., Mrowietz, U., Kragballe, K. et al. National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines. Arch Dermatol Res 305, 637–643 (2013). https://doi.org/10.1007/s00403-013-1341-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-013-1341-x